journal article·2009-10

Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis

Feng Bi, Jing Zhang, Yijing Su, Yan-Chun Tang, Jian-Ning Liu

Biomaterials· Volume 30· Issue 28
Publisher page

Abstract

Thrombolytic therapy is an important treatment for thrombosis, a life-threatening condition in cardiovascular diseases. However, the traditional thrombolytic therapies have often been associated with the risk of severe bleeding. By conjugating urokinase with magnetic nanoparticles (MNPs), we have presented a strategy to control thrombolysis within a specific site. The covalent bioconjugate of urokinase and dextran-coated MNPs was synthesized and isolated. Thrombolysis by the conjugate was studied under a magnetic field in a rat arteriovenous shunt thrombosis model. The magnetic field was generated by two AlNiCo permanent magnets around the site of thrombus. The magnetic field enhanced the thrombolytic efficacy of the conjugate by 5-fold over urokinase with no reduction in plasma fibrinogen and little prolonged bleeding time. It suggested that thrombolysis had been specifically directed to the desired site by the magnetic carrier under the magnetic field. Additionally, the conjugate had a longer half-life than urokinase in circulation.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Protease and Inhibitor Mechanisms · Characterization and Applications of Magnetic Nanoparticles · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (39)

Show source-provided references
1. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin10.1172/JCI115528 ↗
4. Fibrinolysis: an unfinished agenda10.1097/00001721-200007000-00001 ↗
5. New developments in thrombolytic therapy10.1007/978-1-4615-3806-6_35 ↗
6. Towards safer thrombolytic therapy10.1053/shem.2002.34088 ↗
7. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction10.1056/NEJM199309023291001 ↗
8. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation10.1161/01.CIR.77.3.670 ↗
9. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo10.1073/pnas.84.21.7659 ↗
10. Lung endothelium targeting for pulmonary embolism thrombolysis10.1161/01.CIR.0000103685.61137.3D ↗
11. Applications of magnetic nanoparticles in biomedicine10.1088/0022-3727/36/13/201 ↗
12. Molecular imaging in the clinical arena10.1001/jama.293.7.855 ↗
13. Viral-induced self-assembly of magnetic nanoparticles allows the detection of viral particles in biological media10.1021/ja036409g ↗
14. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells10.1038/74464 ↗
15. Tumor regression by targeted gene delivery to the neovasculature10.1126/science.1070200 ↗
16. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia10.1016/S0304-8853(00)01239-7 ↗
17. Locoregional cancer treatment with magnetic drug targeting
18. Effective targeting of magnetic radioactive 90Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results10.1016/0969-8051(94)00124-3 ↗
19. Clinical applications of magnetic drug targeting10.1006/jsre.2000.6030 ↗
20. Magnetically modulated therapeutic systems10.1016/j.ijpharm.2003.03.002 ↗
21. Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors
22. Magnetically driven thrombolytic preparation containing immobilized streptokinase-targeted transport and action
23. Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells10.1016/0049-3848(90)90078-Q ↗
24. Magnetic fluid as a possible drug carrier for thrombosis treatment10.1016/0304-8853(90)90070-7 ↗
25. Fibrinolysis by urokinase endowed with magnetic property10.1016/0006-291X(87)91123-5 ↗
26. Magnetic urokinase: targeting of urokinase to fibrin clot10.1016/S0006-291X(88)80100-1 ↗
27. Improvement of in vitro thrombolysis employing magnetically-guided microspheres10.1016/j.thromres.2007.08.017 ↗
28. Palmacci S, Josephson L. Synthesis of polysaccharide covered superparamagnetic oxide colloids. US Patent No 5262176; 1993.
29. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates10.1021/bc980125h ↗
30. Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats10.1055/s-0038-1646657 ↗
32. Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time10.1016/S0014-2999(01)01432-7 ↗
33. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications10.1016/j.biomaterials.2004.10.012 ↗
34. Synthesis, characterization and targeting of biodegradable magnetic nanocomposite particles by external magnetic fields10.1016/j.jmmm.2004.10.103 ↗
35. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture10.1055/s-0038-1650023 ↗
36. Superparamagnetic iron oxide: pharmacokinetics and toxicity10.2214/ajr.152.1.167 ↗
37. Magnetic nanoparticles in MR imaging and drug delivery10.1016/j.addr.2008.03.018 ↗
38. Nanomedicine
39. Polymerization and dissolution of fibrin under homogeneous magnetic fields10.1063/1.367735 ↗